The drug is the first-ever treatment designed to slow the progression of the disease by reducing the accumulation of amyloid beta protein in the brain.
Eisai says a global clinical study found, compared with a placebo group, lecanemab reduced cognitive and functional decline by 27 percent after 18 months.